Shire Acquires Lumena Pharmaceuticals - - BioPharm International

ADVERTISEMENT

Shire Acquires Lumena Pharmaceuticals



Shire has acquired Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for $260 million.

According to the company, the acquisition of Lumena will expand Shire’s rare disease pipeline and provide future opportunities for Shire’s gastrointestinal business. Lumena Pharmaceuticals brings to Shire two new oral therapeutic compounds for hepatic diseases; LUM001, in Phase 2 with four potential orphan indications and LUM002, ready to enter Phase 2 later in 2014.

LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, which is primarily responsible for recycling bile acids from the intestine to the liver.

Shire does not expect the acquisition of Lumena to result in a change to its previously stated earnings guidance for 2014.

Source: Shire

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines

Click here